Biagio Ricciuti

50PUBLICATIONS
424CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|Jun 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

|May 25, 2026
Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

|May 22, 2026
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.

Pageof 9

Frequent Collaborators

26 joint publications

Mark Magdi Awad

23 joint publications

Joao Victor Alessi

15 joint publications

Alessandro Di Federico

11 joint publications

Lynette Sholl